Oncology

Moderator and AJMC co-editor-in-chief, Dr. Michael Chernew delivers a brief overview of the discussion. The discussion focuses on the use of trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta). Panelists address the patient populations for the two agents and identify which are eligible to take the targeted therapy.

A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels

While American Urological Association and American College of Physician guidelines suggest shared-decision making in prostate specific antigen (PSA) screen testing, most patients have not had part in discussing those decisions.

A clinical research study at Rosewell Park Cancer Institute (RPCI) will be examining a new novel immunotherapy approach to treating advanced melanoma.

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that the healthcare system today is fragmented, if not broken.

Many men are still receiving potentially unnecessary and costly treatments, even after being diagnosed as having prostate cancer with a low risk of dying.